健帆生物
(300529)
| 流通市值：99.50亿 | | | 总市值：155.33亿 |
| 流通股本：5.12亿 | | | 总股本：7.99亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,556,021,993.54 | 1,134,416,582.38 | 547,835,977.14 | 2,677,320,710.76 |
| 营业收入 | 1,556,021,993.54 | 1,134,416,582.38 | 547,835,977.14 | 2,677,320,710.76 |
| 二、营业总成本 | 1,020,308,100.76 | 691,481,834.59 | 331,034,826.7 | 1,711,410,834.56 |
| 营业成本 | 317,573,999.79 | 228,885,193.02 | 105,537,949.67 | 514,607,933.6 |
| 税金及附加 | 27,585,735.8 | 19,818,092.43 | 9,174,764.04 | 43,071,407.11 |
| 销售费用 | 382,811,804.6 | 249,613,213.73 | 113,927,136.54 | 691,993,102.56 |
| 管理费用 | 114,569,886.31 | 75,361,306.48 | 38,464,083.02 | 189,201,207.13 |
| 研发费用 | 147,028,910.64 | 97,455,563.48 | 52,980,606.72 | 240,093,157.22 |
| 财务费用 | 30,737,763.62 | 20,348,465.45 | 10,950,286.71 | 32,444,026.94 |
| 其中:利息费用 | 40,234,062.71 | 26,824,333.3 | 14,239,123.88 | 63,713,298.39 |
| 其中:利息收入 | 10,506,736.68 | 6,987,748.97 | 3,281,412.36 | 30,996,382.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 30,921,869.97 | 21,552,025.71 | 12,815,939.81 | 1,023,228.9 |
| 加:投资收益 | 8,748,220.88 | 8,330,958.77 | 619,349.89 | 42,089,876.63 |
| 资产处置收益 | -2,843,064.1 | -1,413,498.67 | -2,096,892.28 | 3,639,820.27 |
| 资产减值损失(新) | -8,261,933.67 | -6,246,018.68 | 395,252.56 | -10,843,712.79 |
| 信用减值损失(新) | 3,151,415.44 | 2,485,116.42 | 427,280.27 | -1,721,690.32 |
| 其他收益 | 18,950,231.78 | 13,528,172.72 | 7,543,591.49 | 45,268,375.99 |
| 四、营业利润 | 586,380,633.08 | 481,171,504.06 | 236,505,672.18 | 1,045,365,774.88 |
| 加:营业外收入 | 838,449.95 | 181,148.96 | 22,825.48 | 207,090.86 |
| 减:营业外支出 | 35,165,220.08 | 19,448,664.85 | 11,399,090.81 | 38,608,677.82 |
| 五、利润总额 | 552,053,862.95 | 461,903,988.17 | 225,129,406.85 | 1,006,964,187.92 |
| 减:所得税费用 | 100,195,513.49 | 73,235,431.25 | 36,952,099.5 | 192,777,811.13 |
| 六、净利润 | 451,858,349.46 | 388,668,556.92 | 188,177,307.35 | 814,186,376.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 451,858,349.46 | 388,668,556.92 | 188,177,307.35 | 814,186,376.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 453,230,155.4 | 389,722,545.23 | 188,783,596.97 | 820,195,432.44 |
| 少数股东损益 | -1,371,805.94 | -1,053,988.31 | -606,289.62 | -6,009,055.65 |
| 扣除非经常损益后的净利润 | 438,090,907.89 | 372,950,435.32 | 183,768,677.56 | 779,044,218.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.59 | 0.51 | 0.23 | 1.05 |
| (二)稀释每股收益 | 0.57 | 0.49 | 0.23 | 1.07 |
| 八、其他综合收益 | - | - | - | 1,054,450.84 |
| 归属于母公司股东的其他综合收益 | - | - | - | 1,054,450.84 |
| 九、综合收益总额 | 451,858,349.46 | 388,668,556.92 | 188,177,307.35 | 815,240,827.63 |
| 归属于母公司股东的综合收益总额 | 453,230,155.4 | 389,722,545.23 | 188,783,596.97 | 821,249,883.28 |
| 归属于少数股东的综合收益总额 | -1,371,805.94 | -1,053,988.31 | -606,289.62 | -6,009,055.65 |
| 公告日期 | 2025-10-30 | 2025-08-22 | 2025-04-16 | 2025-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |